 Ryan Lanning
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trastuzumab | 1 | 2015 | 89 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 859 | 0.440 |
Why?
| | Receptor, ErbB-2 | 1 | 2015 | 300 | 0.410 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 1879 | 0.350 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2017 | 577 | 0.300 |
Why?
| | Laryngeal Neoplasms | 2 | 2017 | 27 | 0.280 |
Why?
| | Microscopy | 2 | 2022 | 125 | 0.260 |
Why?
| | Breast Neoplasms | 3 | 2015 | 1862 | 0.260 |
Why?
| | Carcinoma | 2 | 2017 | 198 | 0.240 |
Why?
| | Neoplasms | 6 | 2022 | 2097 | 0.220 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 427 | 0.200 |
Why?
| | Glottis | 2 | 2017 | 13 | 0.180 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2019 | 64 | 0.180 |
Why?
| | Drug Carriers | 1 | 2019 | 112 | 0.150 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 188 | 0.150 |
Why?
| | Oxygen | 4 | 2022 | 854 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2017 | 182 | 0.150 |
Why?
| | Cisplatin | 1 | 2019 | 262 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 332 | 0.140 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 13 | 0.140 |
Why?
| | Meningioma | 1 | 2018 | 77 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.140 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 15 | 0.140 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 17 | 0.140 |
Why?
| | Dexamethasone | 1 | 2019 | 317 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 87 | 0.140 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.140 |
Why?
| | Nose Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
| | Ear Neoplasms | 1 | 2016 | 4 | 0.140 |
Why?
| | Ear Canal | 1 | 2016 | 14 | 0.130 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2016 | 16 | 0.130 |
Why?
| | Misonidazole | 1 | 2016 | 1 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 30 | 0.130 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 38 | 0.130 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 117 | 0.130 |
Why?
| | Brachytherapy | 1 | 2016 | 103 | 0.130 |
Why?
| | Nanoparticles | 1 | 2019 | 313 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 124 | 0.120 |
Why?
| | Mastectomy | 1 | 2015 | 99 | 0.120 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 275 | 0.110 |
Why?
| | Quantum Dots | 1 | 2013 | 35 | 0.110 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2015 | 620 | 0.110 |
Why?
| | Aged | 8 | 2018 | 19074 | 0.100 |
Why?
| | Optics and Photonics | 2 | 2003 | 41 | 0.100 |
Why?
| | Propensity Score | 3 | 2017 | 224 | 0.100 |
Why?
| | Middle Aged | 9 | 2018 | 26738 | 0.090 |
Why?
| | Neoplasm Metastasis | 3 | 2019 | 523 | 0.090 |
Why?
| | Spectroscopy, Near-Infrared | 2 | 2002 | 47 | 0.090 |
Why?
| | Melanoma | 1 | 2017 | 620 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2017 | 6347 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1075 | 0.080 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2009 | 18 | 0.080 |
Why?
| | Cell Physiological Phenomena | 1 | 2009 | 23 | 0.080 |
Why?
| | Female | 15 | 2019 | 59523 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2009 | 30 | 0.080 |
Why?
| | Palliative Care | 1 | 2015 | 644 | 0.080 |
Why?
| | Glucose | 1 | 2013 | 897 | 0.080 |
Why?
| | Young Adult | 4 | 2017 | 10472 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 430 | 0.070 |
Why?
| | Adult | 7 | 2018 | 30554 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 275 | 0.070 |
Why?
| | Blood Vessels | 1 | 2007 | 180 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 512 | 0.060 |
Why?
| | Fetal Blood | 1 | 2007 | 270 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2016 | 244 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 811 | 0.060 |
Why?
| | Humans | 16 | 2018 | 114709 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 343 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1430 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 1644 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2002 | 48 | 0.050 |
Why?
| | Angiotensins | 1 | 2022 | 10 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2022 | 9 | 0.050 |
Why?
| | Losartan | 1 | 2022 | 9 | 0.050 |
Why?
| | Mice | 5 | 2022 | 14872 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2007 | 687 | 0.050 |
Why?
| | Databases, Factual | 2 | 2017 | 1125 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3053 | 0.050 |
Why?
| | Animals | 8 | 2022 | 31709 | 0.050 |
Why?
| | Time Factors | 5 | 2017 | 6116 | 0.050 |
Why?
| | Mammography | 1 | 2002 | 105 | 0.050 |
Why?
| | Neoplasm Transplantation | 3 | 2009 | 228 | 0.050 |
Why?
| | Male | 8 | 2018 | 55609 | 0.040 |
Why?
| | Diffusion | 2 | 2011 | 119 | 0.040 |
Why?
| | Photons | 1 | 2000 | 57 | 0.040 |
Why?
| | Micelles | 1 | 2019 | 34 | 0.040 |
Why?
| | Cohort Studies | 2 | 2018 | 4895 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 630 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 29 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 40 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 33 | 0.030 |
Why?
| | United States | 3 | 2017 | 12186 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 795 | 0.030 |
Why?
| | Organs at Risk | 1 | 2016 | 30 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1144 | 0.030 |
Why?
| | Tumor Hypoxia | 1 | 2016 | 5 | 0.030 |
Why?
| | Radiometry | 1 | 2016 | 42 | 0.030 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 68 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 958 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2003 | 756 | 0.030 |
Why?
| | Radiation Protection | 1 | 2016 | 34 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 157 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 200 | 0.030 |
Why?
| | Cochlea | 1 | 2016 | 90 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1121 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 304 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 259 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2017 | 419 | 0.030 |
Why?
| | Infant | 2 | 2017 | 7964 | 0.030 |
Why?
| | Boronic Acids | 1 | 2013 | 33 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1167 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9088 | 0.030 |
Why?
| | Rats | 3 | 2009 | 4958 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1079 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 2711 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 241 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 511 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1841 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2013 | 301 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1356 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2381 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 12556 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 763 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 296 | 0.020 |
Why?
| | Scattering, Radiation | 2 | 2002 | 92 | 0.020 |
Why?
| | Lymphography | 1 | 2009 | 6 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2009 | 17 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 3330 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2009 | 102 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 181 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 17855 | 0.020 |
Why?
| | Chickens | 1 | 2009 | 177 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 68 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 271 | 0.020 |
Why?
| | Collagen Type I | 1 | 2009 | 108 | 0.020 |
Why?
| | Image Enhancement | 1 | 2009 | 159 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 508 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2007 | 83 | 0.020 |
Why?
| | Hyaluronic Acid | 1 | 2009 | 190 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2286 | 0.020 |
Why?
| | Glioblastoma | 1 | 2009 | 253 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 291 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 5047 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 6220 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3535 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9119 | 0.010 |
Why?
| | Indocyanine Green | 1 | 2002 | 12 | 0.010 |
Why?
| | Methylene Blue | 1 | 2002 | 22 | 0.010 |
Why?
| | Coloring Agents | 1 | 2002 | 72 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1470 | 0.010 |
Why?
| | Fibroadenoma | 1 | 2002 | 2 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2637 | 0.010 |
Why?
| | Premenopause | 1 | 2002 | 106 | 0.010 |
Why?
| | Breast | 1 | 2002 | 139 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2007 | 2187 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 812 | 0.010 |
Why?
| | Contrast Media | 1 | 2002 | 345 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 750 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1551 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2002 | 444 | 0.010 |
Why?
| | Water | 1 | 2002 | 396 | 0.010 |
Why?
| | Child | 1 | 2017 | 18422 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 515 | 0.010 |
Why?
| | Hemoglobins | 1 | 2000 | 315 | 0.010 |
Why?
|
|
Lanning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|